Corrigendum: Current status and future perspectives of liquid biopsy in non-small cell lung cancer
Article information
To the Editor,
We found an error in our published article.
Chang S, Hur JY, Choi YL, Lee CH, Kim WS. Current status and future perspectives of liquid biopsy in non-small cell lung cancer. J Pathol Transl Med. 2020; 54(3): 204-212. https://doi.org/10.4132/jptm.2020.02.27.
In the section "FUTURE PERSPECTIVES ON CIRCULATING TUMOR DNA TESTING IN LUNG CANCER," the following sentence was incorrectly stated:
Original:
"However, the overall false-positive rate is 96.4% because of many indeterminate pulmonary nodules."
Corrected:
"However, in the National Lung Screening Trial (NLST), 96.4% of positive low-dose CT screening results were false positives, corresponding to the false discovery rate rather than the conventional false-positive rate."
The original statement incorrectly described the proportion of false-positive results among positive screening results as the overall false-positive rate. The corrected statement clarifies the distinction between these two measures.
We apologize for this error and any confusion it may have caused.